Dapagliflozin for active lupus kidney disease
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests if a diabetes drug called dapagliflozin can help people with active lupus nephritis by reducing protein in the urine and preserving kidney function. It is given in addition to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with lupus and have a kidney biopsy showing lupus nephritis (class III, IV, or V).
- Your lupus kidney disease is active (new or flaring) within the last 6 months.
- You are on standard medications for lupus nephritis, such as mycophenolate, cyclophosphamide, belimumab, or others.
- You have taken steroids for lupus kidney disease in the past 6 months and are on an antimalarial drug and/or blood pressure medication for kidney protection.
- You have significant protein or microalbumin in your urine (at least 0.5 grams per gram of creatinine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
This study tests a medication called an SGLT2 inhibitor (usually used for diabetes, but being studied for kidney disease) to see if it can reduce the amount of protein leaking into the urine in people with chronic kidney disease from lupus nephritis or ANCA-associated vasculitis, which may help protect the kidneys.
This trial tests a new treatment for people with lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and protect kidney function.
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
Hear when a new Lupus Nephritis (LN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.